REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
The Constitution of India was drafted by the Constituent Assembly of India between 1946 and 1949, despite the political disruptions of the Partition. The Government of India Act 1935 was used as a model and framework. Long passages from the Act were included. The constitution describes a federal state with a parliamentary system of democracy. The federal structure was notable for the strength of the central government, which exclusively controlled defence, foreign affairs, railways, ports, and currency. The President, the constitutional head of state, has reserve powers for taking over the administration of a state. The central legislature has two houses: the Lok Sabha, whose delegates are directly elected by the people in general elections every five years, and the Rajya Sabha, whose members are nominated by the elected representatives in the states. The Constitution also includes features not found in the 1935 Act. The definition of fundamental rights is based on the Constitution of the United States, and the constitutional directives, or goals of endeavour, are based on the Constitution of Ireland. An Indian institution recommended by the constitution is the panchayat or village committees. Untouchability is illegal (Article 17) and caste distinctions are derecognised (Articles 15(2) and 16(2)). The promulgation of the Indian Constitution transformed India into a republic within the Commonwealth. The prime minister of India is the head of government and exercises most executive power.
=== Medications === Drugs that might promote remyelination are being studied. These drug may benefit individuals that have had myelin damage, but not yet widespread damage to exposed nerves. In general, these drugs stimulate oligodendrites in some form, which are the cells that produce myelin. Drugs under investigation include metformin (a diabetes drug), clemastine (an anti-histamine) and GSK239512. Metformin is tested in Belgium for individuals with non-active progressive MS, and Canada, for MS patients up to 25 years old. A separate trial in the UK investigates it in combination with clemastine for the treatment of relapsing-remitting MS. One reason it has been challenging to find drugs for progressive MS is the intact blood–brain barrier, which makes it difficult to deliver drugs to the nervous system. During attacks in relapsing MS, the barrier is weakened. BTK inhibitors can cross this barrier to varying degrees, and many are studied for different types of MS. Therapies against EBV are of interest too. An EBV vaccine might help against MS, but there is also a risk the vaccine itself might trigger or worsen MS. Finally, CAR-T therapy is studied as a way to reset the immune system.
== See also == Anthropogenic metabolism – Material and energy turnover of human society Antimetabolite – Chemical that inhibits the use of a metabolite Battery theory Calorimetry – Determining heat transfer in a system by measuring its other properties Isothermal microcalorimetry – Measuring versus elapsed time the net rate of heat flow Inborn errors of metabolism – Class of genetic diseases Iron–sulfur world hypothesis – Hypothetical scenario for the origin of life, a "metabolism first" theory of the origin of life Metabolic disorder – Any disease hindering the body's ability to process and distribute nutrients Microphysiometry Primary nutritional groups – Group of organisms Proto-metabolism – Chemical reactions which turn into modern metabolism Respirometry – Estimation of metabolic rates by measuring heat production Stream metabolism Sulfur metabolism – Set of chemical reactions involving sulfur in living organisms Thermic effect of food – Energy expenditure for processing food Urban metabolism – Model of the flows of materials and energy in cities Water metabolism – Aspect of homeostasis concerning control of the amount of water in an organism Overflow metabolism – Cellular phenomena Oncometabolism Reactome – Database of biological pathways KEGG – Collection of bioinformatics databases
Acral angiofibromas are also termed superficial acral fibromyxomas, digital fibromyxomas, acquired digital fibrokeratomas, acquired periungual fibrokeratomas, garlic clove fibromas, digital fibromas, and cellular digital fibromas. At one time, periungual angiofibromas were regarded as a type of acral angiofibroma (see above description). Acral refers to distal sites of the ears, nose, hands, fingers, feet, and toes. Acral angifibromeae occur primarily in areas close to the nails of fingers and toes (~80% of cases) or, less commonly, palms of the hands or soles of the feet. The tissues of this tumor consists of bland spindle-shaped and star-shaped cells within a collagen fiber-rich stroma containing prominent blood vessels and mast cells.
Sources: en.wikipedia.org
D-Phenylalanine (DPA, D-Phe), sold under the brand names Deprenon, Sabiben, and Sabiden, is an enantiomer of phenylalanine which is described as an antidepressant and is marketed as a prescription drug for medical use in Argentina. The medication has been marketed since at least the 1970s and continued to be available by the 2000s. D-Phenylalanine has been found to act as an enkephalinase inhibitor, an inhibitor of enkephalinase enzymes that break down endogenous opioid peptides called enkephalins. It has been found to produce anti-inflammatory, analgesic, and anti-craving effects in animal studies.
In 2012, a flag based on the arms of the former Cumberland County Council was registered as the flag of Cumberland with the Flag Institute. In 2013, the Secretary of State for Communities and Local Government, Eric Pickles, formally recognised and acknowledged the continued existence of England's 39 historic counties, including Cumberland. In 2021, it was announced that on 1 April 2023 local government in Cumbria would be reorganised into two unitary authorities, one of which is Cumberland and includes most of the historic county, with the exception of Penrith and the surrounding area. The new authority covers 77% of the area and 90% of the population of the historic county.
=== Fish similar in appearance === Northern snakeheads (Channa argus) are commonly mistaken for bowfin because of similarities in appearance, most noticeably their elongated, cylindrical shape and long dorsal fin that runs along their backs. Northern snakeheads are piscivorous fish native to the rivers and estuaries of China, Russia, and Korea that have been introduced and become established in parts of North America. Unlike bowfin, which are native to North America, though, the northern snakehead is considered an invasive species and environmentally harmful there. Some contrasting differences in bowfin include a black eyespot on their caudal peduncle, a tan and olive coloration, a shorter anal fin, a more rounded head, pelvic fins at a greater distance from the pectoral fins than in the northern snakehead, and the presence of the gular plate on the ventral side of the lower jaw. Another noticeable difference is that bowfin scales do not continue uniformly from their body to their head. Bowfin heads are smooth and free of scales, whereas the northern snakehead has scales that uniformly continue from its body through to its head. The burbot (Lota lota), a predatory fish native to streams and lakes of North America and Eurasia, is also commonly mistaken for bowfin. Burbots can be distinguished by their flat head and chin barbel, long anal fin, and pelvic fins situated beneath the pectoral fins.
It has been shown that injection of peptide amphiphile solutions in vivo leads to in situ gel formation due to the presence of counterions in physiological solutions. This, along with the complete biodegradability of the materials, suggests numerous applications in in vitro and in vivo therapies.
Impetigo herpetiformis Intrahepatic cholestasis of pregnancy (cholestasis of pregnancy, jaundice of pregnancy, obstetric cholestasis, prurigo gravidarum) Linea nigra Pemphigoid gestationis (gestational pemphigoid, herpes gestationis) Prurigo gestationis (Besnier prurigo, early-onset prurigo of pregnancy, linear IgM dermatosis of pregnancy, papular dermatitis of pregnancy, prurigo of pregnancy, Spangler's papular dermatitis of pregnancy) Pruritic folliculitis of pregnancy Pruritic urticarial papules and plaques of pregnancy (late-onset prurigo of pregnancy, polymorphic eruption of pregnancy, PUPPP syndrome, toxemic rash of pregnancy, toxic erythema of pregnancy) Striae gravidarum
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.